BTIG analyst Ryan Zimmerman keeps a Neutral rating on Medtronic (MDT) after Centers for Medicare and Medicaid Services provided a proposed national coverage decision for renal denervation. As ...

Let us introduce you to brain-computer interfaces (BCIs): the science-fiction-sounding idea that might just become the next trillion-dollar tech trend. It sounds like a plot point from “Black ...

Shares of Medtronic PLC MDT rallied 1.34% to $87.17 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,204.95 ...

FDA highlights risks from recalled Medtronic devices tied to esophageal injuries and faulty cannulas, with serious health concerns and product warnings issued.

Medtronic, Inc. (NYSE:MDT) ranks among the top stocks for an early retirement portfolio. On June 18, RBC Capital reiterated a $101 price target and an Outperform rating on Medtronic, Inc.

Medtronic plc MDT announced on May 21 its plans to separate its Diabetes business into a separate, publicly traded company. The separation will occur via a two step transaction – an initial ...

Medtronic plc a global leader in medical technology, announced its intent to spin off its Diabetes business into a entity (New Diabetes Company).

In a surprise move, Medtronic plans to spin off its diabetes business. This is Medtronic's smallest business, but also its fastest-growing one. The new entity could be attractive to more growth ...

Medtronic plc (NYSE:MDT) Q4 2025 Earnings Call Transcript May 21, 2025 Medtronic plc beats earnings expectations. Reported EPS is $1.62, expectations were $1.58.

Today's health tech news covers: Medtronic plans to break off diabetes business, ASCO and Google teaming up on AI tool for doctors, and more.

Medical-device maker Medtronic MDT 0.71% plans to separate its diabetes business into a stand-alone company, the company said, in a move that hives off a division that had struggled but recently ...

Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company and forecast 2026 ...